Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print September 19, 2007, doi:10.1212/01.wnl.0000280576.73609.c6)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000280576.73609.c6v1
70/13_Part_2/1079    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in Neurology
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Tintoré, M.
Right arrow Articles by Montalban, X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tintoré, M.
Right arrow Articles by Montalban, X.
Related Collections
Right arrow MRI
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Optic nerve
Right arrow Diplopia (double vision)
Right arrow Cerebrospinal Fluid
Right arrow Prognosis
Right arrow All Demyelinating disease (CNS)
Right arrow Multiple sclerosis
Right arrow Optic neuritis; see Neuro-ophthalmology/Optic Nerve
Right arrow Transverse myelitis
Right arrow Cohort studies
Right arrow Natural history studies (prognosis)
NEUROLOGY 2008;70:1079-1083
© 2008 American Academy of Neurology

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

M. Tintoré, MD, A. Rovira, MD, J. Río, MD, C. Tur, MD, R. Pelayo, MD, C. Nos, MD, N. Téllez, MD, H. Perkal, M. Comabella, MD, J. Sastre-Garriga, MD and X. Montalban, MD

From CENTRE: Unit of Clinical Neuroimmunology (Department of Neurology) (M.T., J.R., C.T., R.P., C.N., N.T., H.P., M.C., J.S.-G., X.M.), Magnetic Resonance Unit (Department of Radiology) (A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Address correspondence and reprint requests to Dr. Mar Tintoré, Unitat de Neuroimmunologia Clinica (UNIC), Edif. Escola d'infermeria planta 2, Hospital Universitari Vall d'Hebron, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain mtintore{at}vhebron.net

Background: To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS).

Methods: From 1995 to 2006, 572 patients with CIS were included in a prospective study. Patients underwent brain MRI and determination of OB within 3 months of first attack. The number and location of lesions and presence of OB were studied. We analyzed time to second attack and to Expanded Disability Status Scale 3.0 according to number of Barkhof criteria (BC) and the presence or absence of OB.

Results: We studied 415 (73%) patients with CIS with both baseline MRI and determination of OB. Patients were followed for a mean of 50 months (SD 31). Compared to the reference group with 0 BC at baseline MRI, patients with one to two BC showed a hazard ratio (HR) for conversion to CDMS of 3.8 (2.0 to 7.2) and patients with three to four BC of 8.9 (4.8 to 16.4). Of the total cohort, OB were positive in 61% of the patients. However, broken down by MRI group, OB were positive in 31% of those with no BC; 69% of those with one to two BC; and 85% of those with three or four BC. The presence of OB increased the risk of a second relapse (HR 1.7; 1.1 to –2.7) independently of baseline MRI but did not modify the development of disability.

Conclusions: Presence of oligoclonal bands doubles the risk for having a second attack, independently of MRI, but does not seem to influence the development of disability.

GLOSSARY: BC = Barkhof criteria; CDMS = clinically definite multiple sclerosis; CIS = clinically isolated syndromes; EDSS = Expanded Disability Status Scale; HR = hazard ratio; MS = multiple sclerosis; OB = oligoclonal bands.


Editorial, page 1059

e-Pub ahead of print on September 19, 2007, at www.neurology.org.

Disclosure: The authors' unit has received research grants from the following companies: Bayer-Shering AG, Biogen-Idec, Sanofi-Aventis, Merck-Serono, and Teva. Mar Tintore, Jordi Rio, and Xavier Montalban have received scientific honoraria and travel expenses from all companies mentioned. Alex Rovira, Carmen Tur, Raúl Pelayo, Carlos Nos, Neus Téllez, Hector Perkal, Manuel Comabella, and Jaume Sastre-Garriga have no conflicts of interest. No financial support was received for the present study.

Received March 28, 2007. Accepted in final form July 3, 2007.


Related articles in Neurology:

CSF analysis in suspected MS: Do bands aid?
Rogier Q. Hintzen and Gavin Giovannoni
Neurology 2008 70: 1059-1060. [Full Text]  



This article has been cited by other articles:


Home page
JWatch NeurologyHome page
Oligoclonal Bands and MRI in First Attack of Multiple Sclerosis
Journal Watch Neurology, June 17, 2008; 2008(617): 2 - 2.
[Full Text]


Home page
NeurologyHome page
R. Q. Hintzen and G. Giovannoni
CSF analysis in suspected MS: Do bands aid?
Neurology, March 25, 2008; 70(13_Part_2): 1059 - 1060.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.